



09-Dec-2021

Dear //PANS/PANDAS Advocacy Group//:

Children with **Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)** may qualify to participate in the ProPANS IVIG clinical research study, sponsored by Octapharma. This clinical research study will be conducted at a select number of medical universities and institutions. The goal of the study is to find out if the investigational study drug, Panzyga, can help children manage inflammation associated with PANS.

All study participants receive access to the IVIG study drug. Study participants visit the study clinic for health assessments about every 3 weeks and the study lasts approximately 6 months.

**Children may be eligible to participate if they meet the following requirements:**

- 6-17 years in age
- Moderate to severe PANS with prominent and stable obsessive-compulsive disorder symptoms
- Onset of initial PANS symptoms was not more than 6 months prior to planned Screening. Or, for children with relapsing symptoms, the initial symptoms were less than 12 months prior to Screening and recurrence is within 6 months of Screening
- Do not have symptoms consistent with autism, schizophrenia, bipolar disorder, or any other psychiatric disorder

**Study participants receive at no cost:**

- Access to the IVIG study drug (Panzyga)
  - All participants will receive the study drug and placebo (no active ingredients). Participants will be randomly assigned to receive the study drug in either the first or second half of the study
- Study support and study-related monitoring by a healthcare team
- Help with study-related travel expenses, including reimbursements for lodging, transportation, and meals may be provided
- The opportunity to help advance PANS research

We would appreciate your help in making sure that parents and legal guardians of potential study participants know the ProPANS IVIG study could be an option. Please consider sharing the attached **flyer** with parents and legal guardians of a child who may qualify.

For clinical trial information – Please visit [ClinicalTrials.gov](https://ClinicalTrials.gov) (Identifier: NCT04508530)

For more information about enrollment in the trial or to find the site nearest you, contact:

**Snehal Udavat**

Clinical operations at Octapharma USA, Inc.

201-604-1124

[snehal.udavat@octapharma.com](mailto:snehal.udavat@octapharma.com)

Sincerely,

**The ProPANS study team**